COVID-19 | Life Science News | NIH | Vaccine
NIH announced investment of $29 million to address COVID-19 disparities
On Apr. 29, 2021, the National Institutes of Health announced it was funding $29 million in additional grants…
Moderna announced an increased global supply for COVID-19 vaccine to up to 3 billion doses in 2022
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
Pfizer and BioNTech submitted request to expand conditional marketing authorization of COMIRNATY in EU to adolescents
On Apr. 29, 2021, Pfizer and BioNTech announced they had submitted a variation to the Conditional Marketing Authorization…
VBI Vaccines announced publication of Challenge Study Data of its eVLP vaccine candidate against COVID-19
On Apr. 28, 2021, VBI Vaccines announced that preclinical data of VBIï¾’s enveloped virus-like particle (eVLP) vaccine candidate,…
Fully vaccinated adults 65 and older are 94% less likely to be hospitalized with COVID-19
On Apr. 28, 2021, the Centers for Disease Control and Prevention (CDC) announced that both mRNA COVID-19 vaccines…
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | Life Science History | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | USDA | Vaccine | WHO
COVID-19 science and reason
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile…
COVID-19 infections survey revealed significant reductions in COVID-19 infections with single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
On Apr. 23, 2021, University of Oxford data from the COVID-19 Infection Survey was the first to show…
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
The WHO announced continued review of emerging evidence on AstraZeneca COVID-19 vaccines
On Apr. 22, 2021, the Strategic Advisory Group of Experts (SAGE) on Immunization annouced updated interim guidance on…
Valneva initiated pivotal phase 3 clinical trial for inactivated, COVID-19 vaccine using Dynavax’s CpG 1018ï¾™ adjuvant
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
RTS,S malaria vaccine reached more than 650 000 children in Ghana, Kenya and Malawi through pilot programme
On Apr. 20, 2021, the World Health Organization (WHO) announced that two years on from the launch of…
Moderna announced new COVID-19 vaccine supply agreement with Israel for 2022
On Apr. 20, 2021, Moderna announced a new supply agreement with Israel for 2022 whereby Israel also retained…
Johnson & Johnson COVID-19 vaccine roll-out resumed in Europe following EMA review
On Apr. 20, 2021, Johnson & Johnson announced that the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee had…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
CureVac Swiss initiated rolling submission process for mRNA-based COVID-19 vaccine candidate with Swissmedic
On Apr. 19, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacï¾’s mRNA-based COVID-19…
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
Moderna announced clinical progress from mRNA Vaccine
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Company’s COVID-19 variant-specific vaccine…
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
Moderna updated clinical and supply on COVID-19 vaccine program
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Company’s COVID-19 variant-specific…
Biotechnology | COVID-19 | Life Science News | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
Pfizer and BioNTech requested regulatory agencies expand Emergency Use of COVID-19 vaccine to adolescents
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
ImmunityBio announced single prime hAd5 COVID-19 vaccination induced 10-fold increase in T cell response
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyï¾’s COVID-19…
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
WHO Global Advisory Committee on Vaccine Safety reported on AstraZeneca COVID-19 vaccine
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…